Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
12/2012
12/27/2012US20120329794 Ab1 KINASE INHIBITORS
12/27/2012US20120329793 Substituted Imidazopyridinyl Compounds
12/27/2012US20120329791 Substituted Imidazopyridinyl-Aminopyridine Compounds
12/27/2012US20120329786 Compounds and therapeutic uses thereof
12/27/2012US20120329782 Azepine inhibitors of janus kinases
12/27/2012US20120329779 Method of Treating Mixed Lineage Leukemia Gene-Rearranged Acute Lymphoblastic Leukemias
12/27/2012US20120329778 Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
12/27/2012US20120329776 Heterocyclic compounds and uses thereof
12/27/2012US20120329774 Thieno-pyridine derivatives as mek inhibitors
12/27/2012US20120329773 Bicyclic ring system substituted amide functionalised phenols as medicaments
12/27/2012US20120329771 Benzylic oxindole pyrimidines
12/27/2012US20120329767 Methods and Compositions for Treating Cancer
12/27/2012US20120329766 Formulation
12/27/2012US20120329765 Medicinal targeted local lipolysis
12/27/2012US20120329761 Use of tigecycline for treatment of cancer
12/27/2012US20120329758 Combined Treatment Utilizing VB-201
12/27/2012US20120329757 Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
12/27/2012US20120329747 Novel hydrazone derivatives having potent antitumor activity toward multi-drug resistant tumor cells
12/27/2012US20120329741 Non-peptide macrocyclic histone deacetylase (hdac) inhibitors and methods of making and using thereof
12/27/2012US20120329734 Mixture and infusion or drink solution
12/27/2012US20120329733 Methods and products related to metabolic interactions in disease
12/27/2012US20120329725 Chimeric Peptides for the Regulation of GTPases
12/27/2012US20120329713 Method for determining likelihood of clinical recurrence or clinically stable disease of prostate cancer after radical prostatectomy
12/27/2012US20120329712 Induction of Differential Stress Resistance and Uses Thereof
12/27/2012US20120329705 Compounds for proteasome enzyme inhibition
12/27/2012US20120329063 Novel means for the diagnosis and therapy of ctcl
12/27/2012US20120328720 Iridoid Based Formulations
12/27/2012US20120328718 Pharmaceutical compositions
12/27/2012US20120328714 Early detection and treatment of lung cancer
12/27/2012US20120328712 Carbon monoxide releasing rhenium compounds for medical use
12/27/2012US20120328705 Magnetic nanomedicine for tumor suppression and therapy
12/27/2012US20120328702 Nanoparticle compositions
12/27/2012US20120328701 Nanoparticle compositions, formulations thereof, and uses therefor
12/27/2012US20120328693 Method for enhancing immune response in the treatment of infectious and malignant diseases
12/27/2012US20120328692 Potent d-peptide antagonists of mdm2 and mdmx for anticancer therapy
12/27/2012US20120328691 Anilinopiperazine derivatives and methods of use thereof
12/27/2012US20120328665 Composite nanoparticle, and preparation process and use thereof
12/27/2012US20120328662 Composition for inhibiting tumor cell proliferation
12/27/2012US20120328661 Coumarin compounds as receptor modulators with therapeutic utility
12/27/2012US20120328647 FORMULATIONS COMPRISING EXTRACTS FROM PRIMITIVE PLANT SPECIES (Mosses, Ferns and Lichens) TO TREAT AND PREVENT CANCERS
12/27/2012US20120328646 Globo H and Related Anti-Cancer Vaccines with Novel Glycolipid Adjuvants
12/27/2012US20120328640 Methods and compositions for the treatment and prevention of cancer
12/27/2012US20120328639 Immunogenic lhrh compositions and methods relating thereto
12/27/2012US20120328638 Mybl2 peptides and vaccines containing the same
12/27/2012US20120328637 Methods and compositions for modulating the activity of the interleukin-35 receptor complex
12/27/2012US20120328636 Kdr peptides and vaccines comprising the same
12/27/2012US20120328634 Immunoconjugates with an Intracellularly-Cleavable Linkage
12/27/2012US20120328632 Inhibition of leukocyte adhesion
12/27/2012US20120328628 Antibodies to conformationally trapped proteins
12/27/2012US20120328627 Chemokine receptor antagonists and use thereof
12/27/2012US20120328625 Targeted binding agents directed to sonic hedgehog homolog and uses thereof
12/27/2012US20120328624 Anti-dll3 antibody
12/27/2012US20120328623 ANTI-erbB3 ANTIBODY
12/27/2012US20120328620 Epidermalgrowth factor receptor mutations
12/27/2012US20120328619 Trispecific Therapeutics Against Acute Myeloid Leukaemia
12/27/2012US20120328618 Dosage regimen for administering a cd19xcd3 bispecific antibody
12/27/2012US20120328617 Method for inhibiting angiogenesis
12/27/2012US20120328612 Anti-flt3 antibodies and methods of using the same
12/27/2012US20120328611 Substituted triazolopyridines
12/27/2012US20120328610 Triazolopyridines
12/27/2012US20120328608 Methods of treating cancer using notch antagonists
12/27/2012US20120328607 Genetic markers indicative of a cancer patient response to trastuzumab (herceptin)
12/27/2012US20120328603 Assays and methods using biomarkers
12/27/2012US20120328599 Inhibitors of receptor tyrosine kinases (rtk) and methods of use thereof
12/27/2012US20120328595 Variant activin receptor polypeptides and uses thereof
12/27/2012US20120328590 Anti-cancer therapeutic strategy to overcome cancer resistance and to enable tailoring treatment to patients
12/27/2012US20120328587 Method for Activating Natural Killer Cells by Tumor Cell Preparation In Vitro
12/27/2012US20120328580 Compounds that enhance atoh1 expression
12/27/2012US20120328575 Modified Oncolytic Viruses
12/27/2012US20120328574 P38 inhibitors
12/27/2012US20120328562 Method and system to remove soluble tnfr1, tnfr2 and il2 in patients
12/27/2012US20120328558 Antibody-light fusion products for cancer therapeutics
12/27/2012US20120328549 Oil compositions
12/27/2012US20120328530 Toluidine blue derivatives as photosensitising compounds
12/27/2012US20120328525 Nanoparticle compositions and components thereof
12/27/2012US20120328524 Anti-gd2 antibodies and methods and uses related thereto
12/27/2012US20120328516 Method of radiotherapy using a radiolabelled rgd peptide
12/27/2012US20120328513 Compositions against cancer antigen liv-1 and uses thereof
12/27/2012US20120328512 Fibrin-Binding Peptides and Conjugates Thereof
12/27/2012US20120328511 Novel Antigen Binding Proteins
12/27/2012CA2877586A1 Treatment and prevention of diseases related to oxidative stress
12/27/2012CA2877474A1 Compounds and therapeutic uses thereof
12/27/2012CA2841203A1 Apoptosis-inducing agent
12/27/2012CA2840461A1 Anti-erbb3 antibody
12/27/2012CA2840373A1 Compounds and methods of prophylaxis and treatment regarding nicotinic receptor antagonists
12/27/2012CA2840170A1 Focused radiation for augmenting immune-based therapies against neoplasms
12/27/2012CA2840161A1 Method for amplifying nk cells
12/27/2012CA2840112A1 7-azaindole derivatives which are suitable for the treatment of cancer diseases
12/27/2012CA2840017A1 Compounds for the treatment of cancers associated with human papillomavirus
12/27/2012CA2839958A1 Heterocyclyl aminoimidazopyridazines
12/27/2012CA2839956A1 Prostaglandin receptor ep2 antagonists, derivatives, compositions, and uses related thereto
12/27/2012CA2839807A1 Combination therapy
12/27/2012CA2839767A1 Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
12/27/2012CA2839621A1 Polymorphs of (s)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide
12/27/2012CA2839552A1 Compositions and methods for the treatment of cancer
12/27/2012CA2838947A1 Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide
12/27/2012CA2838916A1 Metalloenzyme inhibitor compounds
12/27/2012CA2838912A1 Metalloenzyme inhibitor compounds
12/27/2012CA2838909A1 Metalloenzyme inhibitor compounds
12/27/2012CA2837727A1 Substituted imidazopyridinyl-aminopyridine compounds
1 ... 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 ... 2211